Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Genfit S.A.

Genfit is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. It specializes in the discovery and development of drugs targeting liver diseases.

Genfit

GENFIT | 13,887 followers on LinkedIn. Dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs. | GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. 

GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC).

Pascal Prigent

CEO at Aurobac Therapeutics

Florence Sejourne

Chief Corporate Affairs Officer of GENFIT

Jean-Christophe Marcoux

Anne-Helene Monsellato

GENFIT

Sanita Men Bhuyan suffered from ACLF earlier in 2024 and survived it thanks to a liver transplant that was made possible through an experimental change in graft allocation guidance. Sadly, unlike Sanita, very few ACLF patients are considered eligible, nor have enough time, for a transplant. Hence the critical need to discover ACLF treatments that allow liver recovery and expand the liver transplant window. These topics, along with other liver-related subjects, will be discussed next week at the 75th Liver Meeting in San Diego, where GENFIT 's teams will be in attendance. Discover the full story of Sanita's journey through ACLF here : https://lnkd.in/em-efivV #AASLD #LiverTransplant #Transplant #ACLF #LiverDisease

📄 #PressRelease GENFIT Reports Third Quarter 2024 Financial Information 📄 #CommuniquéDePresse GENFIT : Information financière du troisième trimestre 2024 #GENFIT #GNFT #Financialnformation

Cette année encore, pour octobre rose, les équipes de GENFIT s’engagent au travers d’actions de sensibilisation et de prévention au service de la santé des femmes. #OctobreRose #Santé #Cancer #CancerDuSein #Solidarité #LutteContreLeCancer

📢 En 2024, GENFIT et l’Unité mixte de Recherche 1011 ont remporté un appel à projets de Chaire Industrielle, soutenu par la Métropole Européenne de Lille (MEL) et l’ Université de Lille ! Lancé en avril, le projet Chaire HepID-ACLF est une collaboration entre GENFIT et l’UMR 1011, dédiée à l’exploration de nouvelles pistes thérapeutiques pour l’ACLF, une pathologie hépatique sévère encore sans traitement approuvé. En travaillant main dans la main avec des experts scientifiques, nous visons à mieux comprendre la perte d’identité hépatocytaire, un mécanisme potentiellement central dans la défaillance hépatique. Ce partenariat, rendu possible grâce au soutien de la MEL et de l’Université de Lille, allie expertises académique et industrielle pour faire avancer la recherche en santé sur notre territoire. Bravo à guillaume vidal , Manager de projet R&D chez GENFIT, Prof. Bart Staels , Directeur de l’UMR 1011, et au Dr. Jerome Eeckhoute , Chargé de recherche à l’UMR 1011, pour ce projet innovant. 👉 Restez connectés, nous vous en dirons plus très bientôt ! #GENFIT #ChaireIndustrielle #Recherche #Innovation #Santé #UniversitéDeLille #MEL

To celebrate October 17th #WorldOrganDonorDay please listen to DR. Jennifer Lai on the importance of buying ACLF patients more time. To this day, Liver transplantation remains the only treatment, provided that an organ is available and the patient is eligible to receive it. #ACLF #LiverDisease #UnmetNeeds #Transplant https://lnkd.in/eb4yEt5H

Ipsen 's Iqirvo® (elafibranor) has been granted marketing authorization in the UK for Primary Biliary Cholangitis (PBC) – a significant milestone that GENFIT is proud to have contributed to. Another step forward in our commitment to improving the lives of patients with rare liver diseases. “There are many people living with PBC with their needs unmet – be that markers of their disease worsening or symptom burden not being controlled. This can have profound implications for patients and their families, which is why a new treatment option is so vitally important.” said Mo Christie, Head of Patient Services, PBC Foundation. #MHRA #Healthcare #Pharmaceuticals #DrugApproval #PBC #Biotech #LiverDisease To learn more about it : https://lnkd.in/eBDxstr3

This approval marks a historic milestone for GENFIT and strengthens our ability to support our efforts in ACLF, with the objective of being the first to discover a treatment for a disease that currently has none. #LiverDisease #PBC #ACLF #Biotech #DrugDevelopment

Merci à Anne Barloutaud pour cet article sur GENFIT revenant sur nos succès et perspectives. Le lancement d'Iqirvo® d' Ipsen est une étape historique de notre développement et contribuera au financement du pivot stratégique initié vers l’Acute-on-Chronic Liver Failure (ACLF) et d'autres maladies du foie. Pour consulter l'article ➡ https://lnkd.in/ej-UMxWS #Biotech #ACLF #PBC #santé #LiverDisease

We are very proud of the E.U Approval of elafibranor (Iqirvo®), made possible through our partnership with Ipsen. This offers physicians a valuable therapeutic alternative for treating patients with PBC. #PBC #Biotech #LiverDisease #EMA https://lnkd.in/ecShtAg6

📄 #PressRelease GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval 👉 https://lnkd.in/d8bHZnk 📄 #CommuniquéDePresse GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive consécutivement à l’approbation accélérée de la FDA américaine 👉 https://lnkd.in/e7Jaj5T6 #PBC #GENFIT #GNFT #Ipsen

COM:GENFIT

Genfit

Last Close

4.02

22/11 12:47

Market Cap

200.28M

Beta: -

Volume Today

83.61K

Avg: -

Financials Not Available